RARE · Healthcare
Ultragenyx Pharmaceutical In
24/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
32
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$2.6B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About ULTRAGENYX PHARMACEUTICAL IN
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with…
Who's behind the signal
Every informed buyer we can see on RARE, across all three feeds.
Hedge funds · 6
Point72 (Steve Cohen)
New position
AQR Capital Management
Increased +236%
Millennium Management (Englander)
Increased +101%
D.E. Shaw & Co
Increased +266%
Tudor Investment (Paul Tudor Jones)
Increased +299%
Citadel Advisors
Decreased −9%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 1 on record
Disclosures from 2021-08-30 to 2021-08-30
The newest disclosure we hold for this stock is 2021-08-30.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2021-08-30 | Kurt Schrader · D-OR | House | Bought | $1,001 - $15,000 |
Not a model pick — but on our radar.
ULTRAGENYX PHARMACEUTICAL IN isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
1
New positions
4
Increasing
1
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.1×
% of portfolio
0.0%
Position change
NEW
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+236%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+101%
0.0% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+266%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.2×
% of portfolio
0.0%
Position change
+299%
0.0% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−9%
0.0% of Citadel Advisors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to ULTRAGENYX PHARMACEUTICAL IN
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ULTRAGENYX PHARMACEUTICAL IN or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订